A
Advantage Therapeutics
Pharmaceutical company focused on the development of therapeutics for patients suffering from neurodegenerative disease
About Advantage Therapeutics
Advantage Therapeutics is pioneering a novel immunotherapy aimed at treating early-stage Alzheimer's Disease (AD). The company focuses on restoring lipid homeostasis in the brain, which plays a crucial role in the pathogenesis of AD. Their flagship product, AD04, has shown promising results in preclinical and clinical studies, particularly in improving cognition by modulating neuroinflammatory pathways in the hippocampus, a brain region essential for memory. Advantage Therapeutics operates in the biopharmaceutical sector, primarily serving patients diagnosed with early-stage Alzheimer's Disease. The business model revolves around the development and commercialization of proprietary immunotherapies, generating revenue through product sales and potential licensing agreements. The company emphasizes integrity and win-win relationships with stakeholders, ensuring no reliance on modified nucleotides or carrier molecules, thus avoiding license fees.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Miami, United States
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 73.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Sep 2025 | $2.5M | — | National Institute on Aging | ↗ |
| EARLY VCOther financing | Jul 2023 | $10M | $41M | Undisclosed | — |
Growth signals
Latest recorded traffic for Advantage Therapeutics is 1.3K monthly website visits, up 78.1% over the last three months. Advantage Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institute on Aging
Other known investors2 additional known investors
LongevityTech.fund
QuadraScope
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Advantage Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Advantage Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.